Skip to main content

Table 3 Self-reported oral effects of administration of pilocarpine solution to patients with Sjӧgren’s syndrome

From: New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life

Item

 

VAS (10 cm) b

 

Pre-administration

Post-administration at 60 min

Continuous administration

Dryness

7.1 (6.1, 8.0)

4.4 (2.2, 6.5) a

3.7 (2.0, 6.9) a

Thirstiness

6.3 (4.5, 7.9)

2.3 (0.7, 5.4) a

2.4 (1.5, 5.3) a

Stickiness

6.3 (4.8, 7.4)

4.0 (0.7, 5.4)

2.4 (0.9, 6.5)

Altered taste

0.5 (0.3, 4.3)

1.1 (0.5, 4.3)

1.4 (0.5, 3.2)

Painful tongue

4.1 (0.4, 7.8)

1.3 (0.5, 6.4)

2.2 (0.4, 7.0)

  1. a: Significantly different from pre-administration at P < 0.05 (Scheffe’s F test) (n = 21)
  2. bVAS, visual analog scale; Median (1st quartile, 3rd quartile)
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us